INHIBITION OF VIRAL AND CELLULAR PROMOTERS BY HUMAN WILD-TYPE P53

被引:224
|
作者
SUBLER, MA [1 ]
MARTIN, DW [1 ]
DEB, S [1 ]
机构
[1] UNIV TEXAS,HLTH SCI CTR,DEPT MICROBIOL,SAN ANTONIO,TX 78284
关键词
D O I
10.1128/JVI.66.8.4757-4762.1992
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Mutation of the p53 tumor suppressor gene is a recurring event in a variety of human cancers. Wild-type p53 may regulate cell proliferation and has recently been shown to repress transcription from several cellular promoters. We studied the effects of wild-type and mutant human p53 on the human proliferating-cell nuclear antigen promoter and on several viral promoters including the simian virus 40 early promoter-enhancer, the herpes simplex virus type 1 thymidine kinase and UL9 promoters, the human cytomegalovirus major immediate-early promoter-enhancer, and the long terminal repeat promoters of Rous sarcoma virus, human immunodeficiency virus type 1, and human T-cell lymphotropic virus type I. HeLa cells were cotransfected with a wild-type or mutant p53 expression vector and plasmids containing a chloramphenicol acetyltransferase reporter gene under viral (or cellular) promoter control. Expression of wild-type p53 correlated with a consistent and significant (6- to 76-fold) reduction of reporter enzyme activity. A mutation at amino acid 143 of p53 releases this inhibition significantly with all the promoters studied. Expression of a p53 mutated at any one of the five amino acid positions 143, 175, 248, 273, and 281 also correlated with a much smaller (one- to sixfold) reduction of reporter enzyme activity from the herpes simplex virus type 1 thymidine kinase promoter. These mutant forms of p53 are found in various cancer cells. Thus, failure of tumor suppression correlates with loss of the promoter inhibitory effect of p53.
引用
收藏
页码:4757 / 4762
页数:6
相关论文
共 50 条
  • [41] Wild-type p53 reduces radiation hypermutability in p53-mutated human lymphoblast cells
    Zhang, Qinming
    Liu, Yunfeng
    Zhou, Juntling
    Chen, Weihong
    Zhang, Ying
    Liber, Howard L.
    MUTAGENESIS, 2007, 22 (05) : 329 - 334
  • [42] Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers
    Dearth, Lawrence R.
    Qian, Hua
    Wang, Ting
    Baroni, Timothy E.
    Zeng, Jue
    Chen, Stephanie W.
    Yi, Sun Young
    Brachmann, Rainer K.
    CARCINOGENESIS, 2007, 28 (02) : 289 - 298
  • [43] Cellular oxidative stress and the control of apoptosis by wild-type p53, cytotoxic compounds, and cytokines
    Lotem, J
    PeledKamar, M
    Groner, Y
    Sachs, L
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (17) : 9166 - 9171
  • [44] Pharmacological activation of wild-type p53 in the therapy of leukemia
    Kojima, Kensuke
    Ishizawa, Jo
    Andreeff, Michael
    EXPERIMENTAL HEMATOLOGY, 2016, 44 (09) : 791 - 798
  • [45] GEP associates with wild-type p53 in hepatocellular carcinoma
    Cheung, ST
    Wong, SY
    Lee, YT
    Fan, ST
    ONCOLOGY REPORTS, 2006, 15 (06) : 1507 - 1511
  • [46] Wild-type p53 overexpression: What role in tumorigenesis?
    Wolf, JK
    Wharton, JT
    GYNECOLOGIC ONCOLOGY, 1996, 60 (03) : 337 - 338
  • [47] WILD-TYPE HUMAN P53 TRANSACTIVATES THE HUMAN PROLIFERATING CELL NUCLEAR ANTIGEN PROMOTER
    SHIVAKUMAR, CV
    BROWN, DR
    DEB, S
    DEB, SP
    MOLECULAR AND CELLULAR BIOLOGY, 1995, 15 (12) : 6785 - 6793
  • [48] Modulation of MDR/MRP by wild-type and mutant p53
    Bähr, O
    Wick, W
    Weller, M
    JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (05): : 643 - 645
  • [49] Osteocalcin Gene Expression Is Regulated by Wild-Type p53
    Chen, Hankui
    Hays, Emily
    Liboon, Jay
    Neely, Chris
    Kolman, Kevin
    Chandar, Nalini
    CALCIFIED TISSUE INTERNATIONAL, 2011, 89 (05) : 411 - 418
  • [50] Wild-type p53: Tumors can't stand it
    Kastan, Michael B.
    CELL, 2007, 128 (05) : 837 - 840